aa 214 abiotic stress antigr blocker PCR Glycyrrhiza KRAS mutations marker proteins medicinal plant mlcard
FOXO3 Is Expressed in Ovarian Tissues and Acts as an Apoptosis Initiator in Granulosa Cells of Chickens.
FOXO3, which encodes the transcription issue forkhead field O-3 (FoxO3), is a member of the FOXO subfamily of the forkhead field (FOX) household. FOXO3 might be negatively regulated by its phosphorylation by the PI3K/Akt signaling pathway and in the end drives apoptosis when activated.
In mammalian ovaries, the FOXO3 protein regulates atresia and follicle development by selling apoptosis of ovarian granulosa cells. Nonetheless, the precise results of the FOXO3 protein on granulosa apoptosis of avian ovaries haven’t been elucidated. Due to this fact, we studied FOXO3 expression in follicles with completely different group and in any respect hierarchical ranges of rooster follicles.
Through an immunofluorescence assay, the rooster follicular theca in any respect hierarchical ranges had been discovered to be strongly stained with an anti-FOXO3 antibody. In rooster main ovarian granulosa cells, mRNA ranges of proapoptotic elements BNIP3 and BCL2L11 decreased within the absence of FOXO3, and so did PARP-1 and cleaved caspase Three protein ranges.
After remedy with a recombinant FOXO3 protein, PARP-1 and caspase Three protein ranges elevated, together with mRNA ranges of Bnip3 and BCL2L11 (considerably, p<0.05). As well as, FOXO3 was downregulated in rooster granulosa cells when completely different estradiol or FSH concentrations had been utilized.
In conclusion, FOXO3 is expressed in rooster reproductive tissues, together with follicles and ovarian granulosa cells, and promotes apoptosis of rooster ovarian granulosa cells.
Rising views of mitophagy in immunity and autoimmune illnesses.
Mitophagy is a crucial type of autophagy for selective removing of dysfunctional or redundant mitochondria. Accumulating proof implicates elimination of dysfunctional mitochondria as a robust means employed by autophagy to maintain the immune system in verify. The method of mitophagy might prohibit inflammatory cytokine secretion and straight regulate mitochondrial antigen presentation and immune cell homeostasis.
On this evaluate, we describe distinctive pathways of mammalian mitophagy and spotlight latest advances related to its operate in immunity. As well as, we additional talk about the direct and oblique proof linking mitophagy to irritation and autoimmunity underlying the pathogenesis of autoimmune illnesses together with inflammatory bowel illnesses (IBD), systemic lupus erythematosus (SLE) and first biliary cirrhosis (PBC).
Neuroprotective function of BNIP3 underneath oxidative stress by autophagy in neuroblastoma cells.
Reactive oxygen species (ROS) are produced as a result of oxidative stress which has wide selection of affiliation with completely different illnesses together with most cancers, coronary heart failure, diabetes and neurodegenerative illnesses like Alzheimer’s illness, Parkinson’s illness, ischemic and hemorrhagic illnesses.
This examine exhibits the involvement of BNIP3 within the amplification of metabolic pathways associated to mobile high quality management and mobile self defence mechanism within the type of autophagy. We used standard strategies to induce autophagy by treating the cells with H2O2. MTT assay was carried out to look at the mobile viability in confused situation.
MDC staining was carried out for detection of autophagosomes formation which confirmed the autophagy. Moreover, expression of BNIP3 was validated by western blot evaluation with LC3 antibody. From these outcomes it’s clear that BNIP3 performs a key function in defence mechanism by eradicating the misfolded proteins by autophagy.
These outcomes improve the sensible software of BNIP3 in neuroblastoma cells and are useful in lowering the probabilities of neurodegenerative illnesses. Though, the precise mode of motion continues to be unknown however these findings unveil a molecular mechanism for the function of autophagy in cell loss of life and supply perception into advanced relationship between ROS and non-apoptotic programmed cell loss of life.
Agonist antibodies activating the Met receptor defend cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy.
Met, the tyrosine kinase receptor for hepatocyte development issue (HGF), primarily prompts prosurvival pathways, together with safety from apoptosis. On this work, we investigated the cardioprotective mechanisms of Met activation by agonist monoclonal antibodies (mAbs). Cobalt chloride (CoCl2), a chemical mimetic of hypoxia, was used to induce cardiac injury in H9c2 cardiomyoblasts, which resulted in discount of cell viability by (i) caspase-dependent apoptosis and (ii) – surprisingly – autophagy.
Blocking both apoptosis with the caspase inhibitor benzyloxycarbonyl-VAD-fluoromethylketone or autophagosome formation with 3-methyladenine prevented lack of cell viability, which means that each processes contribute to cardiomyoblast harm. Concomitant remedy with Met-activating antibodies or HGF prevented apoptosis and autophagy.
Professional-autophagic Redd1, Bnip3 and phospho-AMPK proteins, that are recognized to advertise autophagy by inactivation of the mTOR pathway, had been induced by CoCl2. Mechanistically, Met agonist antibodies or HGF prevented the inhibition of mTOR and diminished the flux of autophagosome formation.
Accordingly, their anti-autophagic operate was utterly blunted by Temsirolimus, a selected mTOR inhibitor. Focused Met activation was profitable additionally within the setting of low oxygen situations, during which Met agonist antibodies or HGF demonstrated anti-apoptotic and anti-autophagic results. Activation of the Met pathway is thus a promising novel therapeutic device for ischaemic harm.
Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic remedy in glioblastoma.
Antiangiogenic remedy results in devascularization that limits tumor development. Nevertheless, the advantages of angiogenesis inhibitors are sometimes transient and resistance typically develops. On this examine, we explored the speculation that hypoxia attributable to antiangiogenic remedy induces tumor cell autophagy as a cytoprotective adaptive response, thereby selling remedy resistance.
Hypoxia-induced autophagy was depending on signaling by the hypoxia-inducible factor-1α (HIF-1α)/AMPK pathway, and remedy of hypoxic cells with autophagy inhibitors prompted a shift from autophagic to apoptotic cell loss of life in vitro. In glioblastomas, clinically immune to the VEGF-neutralizing antibody bevacizumab, elevated areas of hypoxia and better ranges of autophagy-mediating BNIP3 had been discovered in comparison with pretreatment specimens from the identical sufferers.
When handled with bevacizumab alone, human glioblastoma xenografts confirmed elevated BNIP3 expression and hypoxia-associated development, which might be prevented by addition of the autophagy inhibitor chloroquine. In vivo concentrating on of the important autophagy gene ATG7 additionally disrupted tumor development when mixed with bevacizumab remedy.
Collectively, our findings elucidate a novel mechanism of resistance to antiangiogenic remedy during which hypoxia-mediated autophagy promotes tumor cell survival. One robust implication of our findings is that autophagy inhibitors might assist forestall resistance to antiangiogenic remedy used within the clinic.
Osteopontin stimulates autophagy through integrin/CD44 and p38 MAPK signaling pathways in vascular easy muscle cells.
Osteopontin (OPN) exerts pro-inflammatory impact and is related to the event of stomach aortic aneurysm (AAA). Nevertheless, the molecular mechanism underlying this affiliation stays obscure. Within the current examine, we in contrast gene expression profiles of AAA tissues utilizing microarray assay, and located that OPN was the very best expressed gene (>125-fold).
BNIP3 Antibody |
|||
| 1-CSB-PA050118 | Cusabio |
|
|
|
Description: A polyclonal antibody against BNIP3. Recognizes BNIP3 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
|||
BNIP3 Antibody |
|||
| 1-CSB-PA004979 | Cusabio |
|
|
|
Description: A polyclonal antibody against BNIP3. Recognizes BNIP3 from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
|||
BNIP3 Antibody |
|||
| 1-CSB-PA084239 | Cusabio |
|
|
|
Description: A polyclonal antibody against BNIP3. Recognizes BNIP3 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
BNIP3 Antibody |
|||
| 1-CSB-PA093779 | Cusabio |
|
|
|
Description: A polyclonal antibody against BNIP3. Recognizes BNIP3 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:200-1:1000, IHC:1:25-1:100 |
|||
BNIP3 Antibody |
|||
| 1-CSB-PA618642ESR1HU | Cusabio |
|
|
|
Description: A polyclonal antibody against BNIP3. Recognizes BNIP3 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200 |
|||
BNIP3 Antibody |
|||
| F42817-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: NIP3 is a member of the BCL2/adenovirus E1B 19 kd-interacting protein (BNIP) family. It interacts with the E1B 19 kDa protein which is responsible for the protection of virally-induced cell death, as well as E1B 19 kDa-like sequences of BCL2, also an apoptotic protector. NIP3 contains a BH3 domain and a transmembrane domain, which have been associated with pro-apoptotic function. The dimeric mitochondrial protein is known to induce apoptosis, even in the presence of BCL2. |
|||
BNIP3 Antibody |
|||
| F42817-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
|
Description: NIP3 is a member of the BCL2/adenovirus E1B 19 kd-interacting protein (BNIP) family. It interacts with the E1B 19 kDa protein which is responsible for the protection of virally-induced cell death, as well as E1B 19 kDa-like sequences of BCL2, also an apoptotic protector. NIP3 contains a BH3 domain and a transmembrane domain, which have been associated with pro-apoptotic function. The dimeric mitochondrial protein is known to induce apoptosis, even in the presence of BCL2. |
|||
BNIP3 Antibody |
|||
| RQ4194 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: The Bcl-2 nineteen kilodalton interacting protein 3 (BNIP3 or NIP3), is a hypoxia-inducible proapoptotic member of the Bcl-2 family that induces cell death by associating with the mitochondria. BNIP3, expressed in skeletal muscle and in the brain at low levels, is primarily localized to the nucleus of glial cells of the normal human brain, as well as in the malignant glioma cell line U251. BNIP3 expression in the cytoplasm increases and localizes with the mitochondria, contributing to induction of cell death. Cellular protein BNIP3 interacts with E1B-19K, BCL-2, BCL-xL, and EBV-BHRF1. BNIP3 contains Bcl-2 homology 3 (BH3) domain and COOH-terminal transmembrane (TM) domain. The BH3 domain of BNIP3 mediates Bcl-2/Bcl-X(L) heterodimerization and confers pro-apoptotic activity; whereas the TM domain is critical for homodimerization, pro-apoptotic function, and mitochondrial targeting. |
|||
BNIP3 Antibody |
|||
| R30236 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: The Bcl-2 nineteen kilodalton interacting protein 3(BNIP3 or NIP3), is a hypoxia-inducible proapoptotic member of the Bcl-2 family that induces cell death by associating with the mitochondria. BNIP3, expressed in skeletal muscle and in the brain at low levels, is primarily localized to the nucleus of glial cells of the normal human brain, as well as in the malignant glioma cell line U251. BNIP3 expression in the cytoplasm increases and localizes with the mitochondria, contributing to induction of cell death. Cellular protein BNIP3 interacts with E1B-19K, BCL-2, BCL-xL, and EBV-BHRF1. BNIP3 contains Bcl-2 homology 3(BH3) domain and COOH-terminal transmembrane(TM) domain. The BH3 domain of BNIP3 mediates Bcl-2/Bcl-X(L) heterodimerization and confers pro-apoptotic activity; whereas the TM domain is critical for homodimerization, pro-apoptotic function, and mitochondrial targeting. |
|||
NIP3 / BNIP3 Antibody |
|||
| 48322-100ul | SAB | 100ul | EUR 399.6 |
NIP3 / BNIP3 Antibody |
|||
| 48322-50ul | SAB | 50ul | EUR 286.8 |
BNIP3 Conjugated Antibody |
|||
| C49520 | SAB | 100ul | EUR 476.4 |
BNIP3 Conjugated Antibody |
|||
| C38681 | SAB | 100ul | EUR 476.4 |
BNIP3 Conjugated Antibody |
|||
| C36224 | SAB | 100ul | EUR 476.4 |
Antibody for Human BNIP3 |
|||
| SPC-685D | Stressmarq | 0.1mg | EUR 424.8 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is unconjugated. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A655 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 655. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 390. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A488 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 488. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A565 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 565. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A594 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 594. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A633 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 633. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A680 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 680. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-A700 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to ATTO 700. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-ALP | Stressmarq | 0.1mg | EUR 472.8 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to Alkaline Phosphatase. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-APC | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to APC . |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to APC/Cy7. |
|||
Antibody for Human BNIP3 |
|||
| SPC-685D-BI | Stressmarq | 0.1mg | EUR 475.2 |
|
Description: A polyclonal antibody for BNIP3 from Human | Mouse . The antibody is produced in rabbit after immunization with human synthetic peptide from the C-terminal of human BNIP3. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This BNIP3 antibody is conjugated to Biotin. |
|||
To research the flexibility of OPN to stimulate autophagy as a possible mechanism concerned within the pathogenesis of this illness, we handled vascular easy muscle cells (SMCs) with OPN, and located that OPN considerably elevated the formation of autophagosomes, expression of autophagy-related genes and cell loss of life, whereas blocking the sign by anti-OPN antibody markedly inhibited OPN-induced autophagy and SMC loss of life.
